[ORGANIZATION]
The Lancet Diabetes & Endocrinology
Featured in 10 tracked stories · first seen
Situations
GLP-1 drugs: clinical trends, safety, and market shifts
343 clusters · 1318 sources · last updated
Latest: FDA issues warning for GLP-1 drugs over vision loss risks
The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, neurodegenerative, heart, sleep apnea, and addiction healt
Research on obesity index limitations
5 clusters · 41 sources · last updated
Latest: International study proposes new obesity framework beyond BMI
Scientific studies have increasingly questioned the sufficiency of the Body Mass Index (BMI) for accurately predicting chronic disease risks and assessing obesity. An initial study involving the ChinaHEART cohort of over
Brazil plans semaglutide integration into SUS
12 clusters · 172 sources · last updated
Latest: Anvisa regulates weight-loss medications and seizes irregular supplements
The Brazilian Ministry of Health is progressing with plans to incorporate semaglutide-based weight-loss medications into the Unified Health System (SUS). On September 24, 2026, the Ministry submitted a formal request to
Research into diabetic kidney disease treatments
6 clusters · 15 sources · last updated
Latest: ASN Kidney Week 2026 highlights new therapies and digital tools for CKD
Scientific research into diabetic kidney disease (DKD) is focusing on novel therapeutic targets, improved monitoring markers, and optimized medication timing. Studies in the ‘Chinese Journal of Natural Medicines’ suggest
Also covered in
-
Mauritius reports decline in type 2 diabetes prevalence
[HEALTH] · 3 sources ·
-
Obesity surgery linked to lower dementia risk in diabetes patients
[HEALTH] · 3 sources ·